Invesco
SPRO icon

Invesco’s Spero Therapeutics SPRO Stock Holding History

Invesco’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
64,245
+18,871
+42% +$49.4K ﹤0.01% 3680
2026
Q1 		$106K Buy
45,374
+20,669
+84% +$49.1K ﹤0.01% 3615
2025
Q4 		$57.6K Buy
24,705
+2,605
+12% +$6.05K ﹤0.01% 3693
2025
Q3 		$41.5K Buy
22,100
+7,132
+48% +$15.7K ﹤0.01% 3756
2025
Q2 		$43.4K Buy
+14,968
New +$21.5K ﹤0.01% 3733
2023
Q2 		– Sell
-18,979
Closed -$27.5K – 3938
2023
Q1 		$27.5K Buy
18,979
+6,906
+57% +$11.6K ﹤0.01% 3795
2022
Q4 		$20.9K Buy
+12,073
New +$22.5K ﹤0.01% 3967

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco's SPRO Position: Q2 2026 in Review

Invesco increased its Spero Therapeutics (SPRO) stake by 42% in Q2 2026, buying an estimated $49.4K and bringing the position to 64,245 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Invesco first reported a position in SPRO in Q4 2022 and has held it in 7 quarters since. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Invesco held 64,245 shares of Spero Therapeutics worth $142K as of Q2 2026.
  • Invesco bought 18,871 Spero Therapeutics shares in Q2 2026, an estimated $49.4K.
  • Spero Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3680 holding.
  • Invesco first reported a position in Spero Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.